GNL3L mutations were found in about 6.6% of UCEC patients; the “amplified” type of alterations accounted for most of the alterations in UCS (uterine carcinosarcoma) cases, with a frequency of about 3.51%; and the “deeply deleted” type of alterations accounted for most of the alterations in ESCA, with a frequency of about 2.2% (Figure 4A). The gene discussed is GNL3L; the disease is uterine carcinosarcoma.